10x Genomics (TXG) Total Current Liabilities (2018 - 2026)

10x Genomics has disclosed Total Current Liabilities across 9 years of filings, most recently posting $113.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $113.6 million, up 5.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.6 million (up 5.28% YoY), and the FY2025 annual result was $153.5 million, up 30.45% from the prior year.
• Total Current Liabilities came in at $113.6 million for Q1 2026 at 10x Genomics, down from $153.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $153.5 million in Q4 2025 to a low of $94.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $113.6 million (2026), against an average of $118.0 million.
• Across the five-year window, Total Current Liabilities retreated 21.65% in 2022 and surged 30.45% in 2025, its largest moves.
• 10x Genomics' Total Current Liabilities stood at $131.0 million in 2022, then dropped by 2.9% to $127.2 million in 2023, then decreased by 7.49% to $117.6 million in 2024, then jumped by 30.45% to $153.5 million in 2025, then declined by 25.97% to $113.6 million in 2026.
• The last three Total Current Liabilities figures came in at $113.6 million (Q1 2026), $153.5 million (Q4 2025), and $147.3 million (Q3 2025), per Business Quant data.